Que es un reporte espontaneo?

Notificacion voluntaria de un evento adverso sospechado de estar asociado a un farmaco. Puede venir de healthcare professionals, pacientes, literatura u otras fuentes. Se procesa con MedDRA coding, causality assessment y se transmite electronicamente (E2B).

Que estudios epidemiologicos se usan en PV?

Cohort (incidence rates, relative risk), case-control (rare outcomes, odds ratio), nested case-control, y self-controlled designs (SCCS, case-crossover). Usan EHRs, claims databases y registries. Cuantifican risk en poblaciones reales.

Que contiene un PSUR?

Safety specification, summary of safety concerns, benefit-risk assessment, signal evaluation, cumulative exposure, worldwide safety data, adverse reactions, clinical trial data, signal management actions, y risk management update.

Como se maneja una crisis de seguridad?

Crisis team con medical, regulatory, legal, communications. Rapid assessment de data. Regulatory notification. Acciones: label update, Dear HCP letter, restrictions, suspension. Communication proactiva y transparente. Post-crisis monitoring y lessons learned.

Farmacovigilancia Post-Marketing de Peptidos

Categorías: Metodología de Investigación, Protocolos de Seguridad, Información General

La farmacovigilancia post-marketing monitorea seguridad en poblaciones del mundo real. Detecta eventos raros, interacciones y problemas no identificados en ensayos clinicos.

Resumen Simplificado

Post-marketing surveillance incluye spontaneous reporting, epidemiological studies, registries y risk evaluation.

Sistemas de farmacovigilancia

PV systems son obligatorios. Global requirements. ICH guidelines. E2A-E2F. Regional requirements. FDA. EMA. Local authorities. Chile ISP. Company responsibilities. Qualified person. PV system. SOPs. Database. Training. Quality system. Spontaneous reporting. Healthcare professionals. Patients. Consumers. Literature monitoring. Medical journals. Databases. Regulatory intelligence. Dear healthcare provider letters. Safety alerts. Database requirements. Validation. 21 CFR Part 11. GVP compliance. Good pharmacovigilance practice. Audit readiness. Inspection preparedness. PV system detects signals. Enables rapid response. Protects patients worldwide.

Reportes espontaneos y processing

Spontaneous reports son core. Sources. Healthcare professionals. Physicians. Pharmacists. Nurses. Patients. Direct reports. Clinical trials. Solicited reports. Literature. Case reports. Media. Internet. Social media. Data elements. Patient identifier. Reporter. Suspect drug. Dose. Route. Duration. Adverse event. Description. Onset date. Outcome. Concomitant medications. Medical history. Case processing. Triage. Duplicate check. Validation. MedDRA coding. Drug coding. WHODrug. Causality assessment. WHO-UMC. Naranjo algorithm. Seriousness criteria. Death. Life-threatening. Hospitalization. Disability. Congenital anomaly. Important medical event. Reportability. Expedited. 15 days. Periodic. Aggregate. Transmission. E2B format. Electronic submission. Processing quality is critical. Accurate data enables signal detection.

Estudios epidemiologicos

Epidemiological studies complement reports. Study types. Cohort studies. Exposed vs unexposed. Follow-up time. Incidence rates. Relative risk. Case-control studies. Cases vs controls. Odds ratio. Rare outcomes. Nested case-control. Within cohort. Efficient. Self-controlled designs. SCCS. Case-crossover. Within-subject comparison. Confounding reduced. Data sources. Electronic health records. Claims databases. Registries. Disease-specific. Product-specific. Pregnancy registries. Biobanks. Linkage capabilities. Strengths. Real-world population. Large sample size. Long follow-up. Limitations. Confounding. Selection bias. Information bias. Missing data. Drug exposure misclassification. Epidemiology quantifies risk. Estimates incidence. Supports benefit-risk assessment.

Registros de peptidos

Registries collect data systematically. Product registries. All patients on product. Exposure tracking. Outcome capture. Disease registries. Specific condition. Treatment patterns. Outcomes. Pregnancy registries. Exposure during pregnancy. Birth outcomes. Teratogenicity signals. Long-term outcomes. Child development. Registry design. Objectives. Population. Data elements. Follow-up schedule. Data sources. Primary collection. Secondary linkage. Quality control. Validation. Completeness checks. Follow-up procedures. Analysis plan. Descriptive. Comparative. Risk factors. Limitations. Selection bias. Loss to follow-up. Confounding. Sample size. Registry advantages. Real-world data. Long-term follow-up. Rare populations. Signal refinement. Regulatory use. Post-authorization effectiveness. Safety studies.

Reportes periodicos de seguridad

Periodic safety reports son obligatorios. PSUR. Periodic Safety Update Report. PBRER. Periodic Benefit-Risk Evaluation Report. EMA format. ICH E2C(R2). Frequency. Every 6 months first 2 years. Annually years 3-5. Every 5 years after. Or per local requirement. Content. Safety specification. Summary of safety concerns. Benefit-risk assessment. Signal evaluation. Cumulative exposure. Worldwide market experience. Adverse reaction data. Clinical trial data. Literature. Signal management. Actions taken. Proposals. Risk management update. US equivalent. PSUR equivalent. NDA annual reports. IND annual reports. Regional variations. Brazil. ANVISA. China. NMPA. Japan. PMDA. Report quality matters. Regulatory review. Actions may result. Label changes. Restrictions. Withdrawal in extreme cases.

Respuesta a crisis de seguridad

Safety crisis response. Triggers. Unexpected serious risk. New contraindication. Major restriction. Withdrawal consideration. Media attention. Public concern. Crisis team. Medical officer. Regulatory affairs. Legal. Communications. Senior management. Rapid assessment. Data gathering. Expert consultation. Risk quantification. Benefit-risk re-evaluation. Regulatory notification. Urgent restrictions. Dear healthcare provider letters. Press releases. Website updates. Media strategy. Proactive communication. Transparency. Stakeholder engagement. Patients. Healthcare professionals. Regulators. Actions. Label update. Dear HCP letter. Risk minimization. Educational materials. Monitoring program. Restricted access. Suspension. Withdrawal. Post-crisis. Monitoring effectiveness. Ongoing evaluation. Lessons learned. System improvement. Crisis management protects patients. Preserves trust. Ensures appropriate use.

Hallazgos Clave

Sistemas PV requieren qualified person, SOPs, database validada y GVP compliance
Case processing incluye triage, MedDRA coding, causality, seriousness y E2B transmission
Estudios epidemiologicos usan cohort, case-control y self-controlled designs con EHR/claims data
Registries capturan datos long-term de productos, enfermedades especificas o embarazo
PSURs/PBRERs son reportes periodicos con cumulative safety y benefit-risk update
Crisis response requiere team dedicado, rapid assessment, communication y regulatory notification

Más artículos en Metodología de Investigación

Más artículos en Protocolos de Seguridad

Preguntas frecuentes

Que es un reporte espontaneo?: Notificacion voluntaria de un evento adverso sospechado de estar asociado a un farmaco. Puede venir de healthcare professionals, pacientes, literatura u otras fuentes. Se procesa con MedDRA coding, causality assessment y se transmite electronicamente (E2B).
Que estudios epidemiologicos se usan en PV?: Cohort (incidence rates, relative risk), case-control (rare outcomes, odds ratio), nested case-control, y self-controlled designs (SCCS, case-crossover). Usan EHRs, claims databases y registries. Cuantifican risk en poblaciones reales.
Que contiene un PSUR?: Safety specification, summary of safety concerns, benefit-risk assessment, signal evaluation, cumulative exposure, worldwide safety data, adverse reactions, clinical trial data, signal management actions, y risk management update.
Como se maneja una crisis de seguridad?: Crisis team con medical, regulatory, legal, communications. Rapid assessment de data. Regulatory notification. Acciones: label update, Dear HCP letter, restrictions, suspension. Communication proactiva y transparente. Post-crisis monitoring y lessons learned.

Volver a la biblioteca de investigación